Silence Therapeutics (SLN) Earnings Date
The next earnings date for Silence Therapeutics (SLN) is around Mar 4, 2027, estimated from its own calendar.
- Next earnings date
- Around Mar 4, 2027
- estimated from its own calendar · quarter ending Dec '26
- Latest stored quarter
- EPS −0.08
- revenue $0.00 · reported Nov 12, 2026
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
Estimate-vs-actual scoring began Nov 2026. Earlier quarters predate our snapshots, so their surprise stays "—". We never backfill an estimate we didn't observe.
| Report | Act EPS | Act rev | Reaction |
|---|---|---|---|
| Nov 12, 20268-K, before open · 8:00 am ET | −0.08 | $0.00 | +0.2%release day |
| Aug 10, 20268-K, before open · 7:20 am ET | −0.09 | $0.00 | +29.1%release day |
| May 7, 20268-K, before open · 8:15 am ET | −0.11 | $422,000.00 | −5.6%release day |
| Mar 5, 20268-K, before open · 7:40 am ET | −0.09 | $34,000.00 | −4.8%release day |
| Nov 6, 20258-K, before open · 7:38 am ET | −0.15 | $159,000.00 | +3.4%release day |
| Aug 7, 20258-K, before open · 7:35 am ET | −0.19 | $224,000.00 | +1.1%release day |
| May 8, 20258-K, before open · 8:10 am ET | −0.20 | $142,000.00 | −3.8%release day |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 2 | 2 | 3 | 3 |
| Avg estimate | −0.09 | −0.12 | −0.36 | −0.55 |
| Low estimate | −0.09 | −0.12 | −0.50 | −0.81 |
| High estimate | −0.08 | −0.12 | −0.16 | −0.22 |
| Year-ago EPS | −0.09 | −0.11 | −0.63 | −0.36E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 5 | 4 | 5 | 4 |
| Avg estimate | $87,200.00 | $168,600.00 | $417,429.00 | $1.3M |
| Low estimate | $87,100.00 | $168,600.00 | $407,247.00 | $176,158.00 |
| High estimate | $87,300.00 | $168,600.00 | $427,610.00 | $2.4M |
| Year-ago revenue | $34,000.00 | $422,000.00 | $559,000.00 | $417,429.00E |
| Implied growth | +156.5% | −60.0% | −25.3% | +208.8% |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −0.09 | −0.12 | −0.36 | −0.55 |
| 7 days ago | — | — | — | — |
| 30 days ago | — | — | — | — |
| 60 days ago | — | — | — | — |
| 90 days ago | — | — | — | — |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus has held at $−0.09 across 1 tracked day since Nov 15, 2026. A bar that has not moved is an answer, not a gap: a beat against a flat bar is a real beat. Per-analyst up/down revision counts aren't in our data feed.
Common questions
When does Silence Therapeutics report earnings next?
Silence Therapeutics' next earnings date is around Mar 4, 2027, estimated from its own calendar.
What were Silence Therapeutics' latest quarterly earnings?
Silence Therapeutics reported diluted EPS of −0.08 and revenue of $0.00 on Nov 12, 2026.
How did Silence Therapeutics' stock move after its last earnings report?
Silence Therapeutics moved +0.2% in the session after its Nov 12, 2026 report.

